Acquisition of Radioactive products (PLUVICTO and LUTATHERA)

The Defense Health Agency (DHA) intends to award a Firm-Fixed Price contract to Novartis Pharmaceuticals Corporation for the acquisition of radioactive products (PLUVICTO and LUTATHERA) used for imaging patient's disease. The products must be U.S. FDA Approved, and Novartis Pharmaceuticals Corporation is the FDA Approved Manufacturer. • The total cost for the Purchase Order is estimated at $578,754.32. • The associated NAICS code applicable to this requirement is 325412 - Pharmaceutical Preparation Manufacturer. • Interested parties may express their interest and provide a capabilities statement by January 11, 2026, at 7:00 AM EST.